Loading clinical trials...
Loading clinical trials...
Febrile Seizures in Children: Association of Thyroxine (T4), Epinephrine, and Norepinephrine Levels With Seizure Characteristics and Hospital Outcomes-A Prospective Controlled Observational Study
Febrile seizures are the most common seizure type in early childhood and usually occur during febrile illnesses. Although most febrile seizures are benign, the biological stress response during seizures is not fully understood. In particular, changes in thyroid hormones and stress-related hormones released by the sympathetic nervous system may play a role in seizure characteristics and clinical outcomes. This prospective observational study aims to evaluate the neuroendocrine response in children presenting with febrile seizures by measuring serum thyroxine (T4), epinephrine, and norepinephrine levels. These measurements will be obtained during the acute phase after seizure cessation and compared with levels measured at recovery and with febrile children without seizures. The study will examine the relationship between neuroendocrine marker levels and seizure characteristics such as seizure duration and recurrence, as well as clinical outcomes including length of hospital stay and need for pediatric intensive care unit admission. By improving understanding of the hormonal stress response associated with febrile seizures, this study aims to contribute to the knowledge of seizure pathophysiology in childhood and may help identify biological factors associated with more severe clinical courses.
Febrile seizures represent a common pediatric neurological emergency and are triggered by fever-related systemic stress rather than primary epileptic pathology. Acute febrile seizures are accompanied by activation of the hypothalamic-pituitary-thyroid axis and the sympathetic-adrenal system, resulting in measurable changes in circulating thyroid hormones and catecholamines. However, the magnitude and clinical relevance of this neuroendocrine response remain incompletely characterized. This study is designed as a prospective, observational, case-control investigation conducted in a pediatric emergency department setting. Children aged 6 months to 5 years presenting with febrile seizures will be enrolled as the case group. An age-matched control group will consist of febrile children without seizures. Participants will not be assigned to any intervention, and all clinical management will follow standard care practices. In the febrile seizure group, blood samples for measurement of serum thyroxine (T4), epinephrine, and norepinephrine will be obtained within 30 minutes after seizure cessation to capture the acute neuroendocrine stress response. Additional samples will be collected prior to hospital discharge to assess recovery-phase hormone levels. In the control group, blood samples will be collected during the febrile episode at the time of clinical evaluation. All laboratory analyses will be performed using validated methods under standardized conditions. Clinical data collected will include demographic characteristics, fever features, seizure type and duration, recurrence during hospitalization, treatment administered, length of hospital stay, and requirement for pediatric intensive care unit admission. The primary objective is to evaluate associations between acute-phase neuroendocrine marker levels and seizure characteristics, particularly seizure duration and recurrence. Secondary objectives include comparisons between febrile seizure patients and febrile controls, as well as associations between hormone levels and clinical outcomes. Statistical analyses will include descriptive methods, group comparisons using parametric or nonparametric tests as appropriate, correlation analyses, and multivariable regression models adjusting for relevant confounders such as age, sex, peak temperature, seizure type, and treatment exposure. The study aims to provide mechanistic insight into the neuroendocrine stress response associated with febrile seizures and to explore its potential relationship with disease severity and short-term outcomes.
Age
0 - 5 years
Sex
ALL
Healthy Volunteers
No
Aydin Adnan Menderes University Hospital
Aydin, Aydın, Turkey (Türkiye)
Start Date
March 1, 2026
Primary Completion Date
March 1, 2027
Completion Date
March 1, 2027
Last Updated
March 11, 2026
120
ESTIMATED participants
Lead Sponsor
Aydin Adnan Menderes University
NCT07103148
NCT07324863
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06694766